Source:http://linkedlifedata.com/resource/pubmed/id/14984358
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
5 Suppl
|
pubmed:dateCreated |
2004-2-26
|
pubmed:abstractText |
Osteoporosis is: (1) Underrated. Currently costs about 7 billion dollars annually in Australia. Has high morbidity and 2-3-fold increase in risk of death after any major osteoporotic fracture. Genetic factors contribute highly to risk, modified by lifestyle and hormonal factors. (2) Underdiagnosed. Bone density is a good predictor of subsequent risk. Anyone with a low-trauma fracture has osteoporosis unless proven otherwise. Every individual with a low trauma fracture should be investigated for exclusion of underlying osteoporosis and considered for effective treatment to reduce future fracture risk. More than 75% of women and about 90% of men with a high likelihood of osteoporosis are not investigated. (3) Undertreated. More than 75% of those affected are not treated. Effective treatments (eg, hormone replacement therapy, selective oestrogen receptor modifiers and bisphosphonates) reduce fracture risk by 30%-60%. Simple measures like vitamin D and calcium supplementation and use of hip protectors can reduce hip fractures, particularly in institutionalised and housebound elderly people
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Calcium, Dietary,
http://linkedlifedata.com/resource/pubmed/chemical/Cholecalciferol,
http://linkedlifedata.com/resource/pubmed/chemical/Diphosphonates,
http://linkedlifedata.com/resource/pubmed/chemical/Raloxifene,
http://linkedlifedata.com/resource/pubmed/chemical/Selective Estrogen Receptor...
|
pubmed:status |
MEDLINE
|
pubmed:month |
Mar
|
pubmed:issn |
0025-729X
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:day |
1
|
pubmed:volume |
180
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
S18-22
|
pubmed:dateRevised |
2005-11-16
|
pubmed:meshHeading |
pubmed-meshheading:14984358-Aged,
pubmed-meshheading:14984358-Bone Density,
pubmed-meshheading:14984358-Calcium, Dietary,
pubmed-meshheading:14984358-Cholecalciferol,
pubmed-meshheading:14984358-Diagnostic Errors,
pubmed-meshheading:14984358-Diphosphonates,
pubmed-meshheading:14984358-Estrogen Replacement Therapy,
pubmed-meshheading:14984358-Female,
pubmed-meshheading:14984358-Fractures, Spontaneous,
pubmed-meshheading:14984358-Humans,
pubmed-meshheading:14984358-Male,
pubmed-meshheading:14984358-Osteoporosis,
pubmed-meshheading:14984358-Raloxifene,
pubmed-meshheading:14984358-Risk Factors,
pubmed-meshheading:14984358-Selective Estrogen Receptor Modulators,
pubmed-meshheading:14984358-Treatment Failure
|
pubmed:year |
2004
|
pubmed:articleTitle |
Osteoporosis: underrated, underdiagnosed and undertreated.
|
pubmed:affiliation |
Bone and Mineral Research Program, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia.
|
pubmed:publicationType |
Journal Article,
Review
|